Media hub

Researchers at the Centenary Institute and the University of Technology Sydney have identified a new drug target for the treatment and prevention of chronic obstructive pulmonary disease (COPD), an inflammatory lung disease that causes airway blockage and that makes it difficult to breathe.

The Centenary Institute welcomes the NSW Government’s commitment to fund a new biomedical complex in Camperdown. The Chair of the Centenary Institute Board, Joseph Carrozzi AM, and its Executive Director, Professor Mathew Vadas AO, are thrilled that a biomedical complex, the Sydney Biomedical Accelerator (SBA), will now be a reality.

Researchers from the Centenary Institute and the University of Technology Sydney have published the first study showing why people with chronic obstructive pulmonary disease (COPD) are at higher risk of developing severe COVID-19.

Centenary Institute research has revealed new insight into tackling mycobacterial infections which are responsible for chronic diseases that include tuberculosis (TB), leprosy and serious skin ulcerations.

Dr Annalicia Vaughan from the Centenary UTS Centre for Inflammation is the successful recipient of the Kenyon Foundation Inflammation Award for 2022. The Award, valued at $20,000, will support Dr Vaughan’s study into identifying new microbial-derived biomarkers for the early diagnosis and treatment of lung cancer. The leading cause of cancer death, lung cancer is ...

Centenary Institute researchers have uncovered new insight into Mycobacterium abscessus, a highly drug-resistant bacteria that can cause serious infection and lung damage in vulnerable people. The bacteria is considered an emerging health threat with infection numbers on the rise globally. Commonly found in soil, dust and water, Mycobacterium abscessus is closely related to the bacteria ...

Research led by the Centenary Institute and the Harvard Medical School, Boston, shows that a compound present in current beta blocker treatments could be repurposed to increase efficiency and safety of infantile hemangioma therapies.

Two Centenary Institute scientists have been awarded grants totalling $4.3 million from the Cancer Institute NSW to undertake critical cancer related medical research.

The Centenary Institute has announced it will establish a new precision medicine laboratory, enabling world-leading research into the use of theranostics to treat cancer, thanks to a grant from the Australian Cancer Research Foundation (ACRF).

Research led by the Centenary Institute and University of Technology Sydney has identified a small RNA molecule called microRNA-21 as a therapeutic target and its inhibition as a potential treatment for chronic obstructive pulmonary disease (COPD).

World-leading research into cardiovascular disease has been boosted with three researchers from the Centenary Institute securing Cardiovascular Research Capacity Program grants from the NSW Government.

New research by the Centenary Institute suggests that commonly prescribed anticoagulants – medicines, such as aspirin, that help prevent blood clots – may make urinary tract infections (UTIs) more severe.